ATE229530T1 - Tetrahydropyridin-(oder 4-hydroxypiperidin) alkylazole mit sigma und/oder 5ht 1a-rezeptor aktivität - Google Patents
Tetrahydropyridin-(oder 4-hydroxypiperidin) alkylazole mit sigma und/oder 5ht 1a-rezeptor aktivitätInfo
- Publication number
- ATE229530T1 ATE229530T1 AT95928478T AT95928478T ATE229530T1 AT E229530 T1 ATE229530 T1 AT E229530T1 AT 95928478 T AT95928478 T AT 95928478T AT 95928478 T AT95928478 T AT 95928478T AT E229530 T1 ATE229530 T1 AT E229530T1
- Authority
- AT
- Austria
- Prior art keywords
- alkylazoles
- hydroxypiperidine
- tetrahydropyridine
- sigma
- receptor activity
- Prior art date
Links
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 title 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 title 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 title 1
- 108010085082 sigma receptors Proteins 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000000044 Amnesia Diseases 0.000 abstract 1
- 208000031091 Amnestic disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 230000006986 amnesia Effects 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000036461 convulsion Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D521/00—Heterocyclic compounds containing unspecified hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9409443A FR2723091B1 (fr) | 1994-07-29 | 1994-07-29 | Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles |
| PCT/EP1995/002978 WO1996004287A1 (fr) | 1994-07-29 | 1995-07-26 | Tetrahydropyridine-(ou 4-hydroxypiperidine) alkylazoles ayant une activite pour les recepteurs sigma et/ou 5ht1a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE229530T1 true ATE229530T1 (de) | 2002-12-15 |
Family
ID=9465902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95928478T ATE229530T1 (de) | 1994-07-29 | 1995-07-26 | Tetrahydropyridin-(oder 4-hydroxypiperidin) alkylazole mit sigma und/oder 5ht 1a-rezeptor aktivität |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US5731331A (de) |
| EP (1) | EP0721455B9 (de) |
| JP (2) | JP4035787B2 (de) |
| KR (1) | KR100389785B1 (de) |
| CN (1) | CN1120167C (de) |
| AT (1) | ATE229530T1 (de) |
| AU (1) | AU712479B2 (de) |
| BR (1) | BR9506292A (de) |
| CA (1) | CA2172986A1 (de) |
| CZ (1) | CZ293123B6 (de) |
| DE (1) | DE69529142T2 (de) |
| DK (1) | DK0721455T3 (de) |
| FI (1) | FI116386B (de) |
| FR (1) | FR2723091B1 (de) |
| HU (1) | HU220088B (de) |
| NO (1) | NO309379B1 (de) |
| NZ (1) | NZ291172A (de) |
| PL (1) | PL183766B1 (de) |
| PT (1) | PT721455E (de) |
| RU (1) | RU2168507C2 (de) |
| WO (1) | WO1996004287A1 (de) |
| ZA (1) | ZA956314B (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2723091B1 (fr) * | 1994-07-29 | 1996-11-08 | Esteve Labor Dr | Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles |
| FR2742052B1 (fr) * | 1995-12-12 | 1998-04-10 | Esteve Labor Dr | Utilisation des derives 1-(4-(4-aryl (ou heteroaryl)-1-piper azinyl)-buty)-1h-azole pour le traitement de la depression, des troubles obsessifs compulsifs, l'apnee du sommeil, les dysfonctions sexuelles, l'emese et le mal des transports |
| GB9613423D0 (en) * | 1996-06-26 | 1996-08-28 | Lilly Industries Ltd | Pharmaceutical compounds |
| HUP9602763A3 (en) * | 1996-10-09 | 1999-05-28 | Egyt Gyogyszervegyeszeti Gyar | 3-phenyl isoxazole derivatives, process for producing them and pharmaceutical compositions containing the same |
| US5919802A (en) * | 1997-12-05 | 1999-07-06 | Princeton University | Methods of preventing and/or treating temporal lobe epilepsy |
| ES2151828B1 (es) * | 1998-07-10 | 2001-08-16 | Esteve Labor Dr | Empleo de derivados de tetrahidropiridinas (ohidroxi-piperidinas)-b utilazoles en la elaboracion de un medicamento para el tratamiento del dolor. |
| US6046331A (en) * | 1998-12-17 | 2000-04-04 | Synaptic Pharmaceutical Corporation | Imidazolones and their use in treating benign prostatic hyperplasia and other disorders |
| GB2355456A (en) | 1999-09-30 | 2001-04-25 | Merck & Co Inc | Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists |
| UA73981C2 (en) * | 2000-03-10 | 2005-10-17 | Merck Patent Gmbh | (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit |
| DE10109867A1 (de) * | 2001-03-01 | 2002-09-05 | Abbott Gmbh & Co Kg | Verwendung von Triazolverbindungen zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie |
| DE10109866A1 (de) * | 2001-03-01 | 2002-09-05 | Abbott Gmbh & Co Kg | Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie |
| ES2251317B1 (es) * | 2004-10-14 | 2007-03-16 | Laboratorios Del Dr. Esteve, S.A. | Inhibidores del receptor sigma. |
| EP1634873A1 (de) | 2004-08-27 | 2006-03-15 | Laboratorios Del Dr. Esteve, S.A. | Sigmarezeptor-Inhibitoren |
| ES2251316B1 (es) * | 2004-10-14 | 2007-03-16 | Laboratorios Del Dr. Esteve, S.A. | Inhibidores del receptor sigma. |
| ATE520668T1 (de) * | 2004-08-27 | 2011-09-15 | Esteve Labor Dr | Sigmarezeptor-inhibitoren |
| KR100871077B1 (ko) * | 2007-05-11 | 2008-11-28 | 한국화학연구원 | 아릴 피페리딘기-함유 이미다졸 유도체, 이의 제조방법 및이를 유효성분으로 포함하는 약학적 조성물 |
| KR100893394B1 (ko) * | 2007-05-11 | 2009-04-17 | 한국화학연구원 | 아릴 피페리딘기-함유 이미다졸 유도체, 이의 제조방법 및이를 유효성분으로 포함하는 약학적 조성물 |
| KR100895998B1 (ko) * | 2007-05-11 | 2009-05-07 | 한국화학연구원 | 아릴 피페리딘기-함유 이미다졸 유도체, 이의 제조방법 및이를 유효성분으로 포함하는 약학적 조성물 |
| WO2008140239A1 (en) * | 2007-05-11 | 2008-11-20 | Korea Research Institute Of Chemical Technology | Imidazole derivatives having aryl piperidine substituent, method for preparation thereof and pharmaceutical compositions containing same |
| CA2781716A1 (en) | 2009-12-04 | 2011-06-09 | Sunovion Pharmaceuticals Inc. | Multicyclic thieno compounds and use thereof for the treatment of a neurological disorder |
| SG10202100751YA (en) | 2016-07-29 | 2021-03-30 | Sunovion Pharmaceuticals Inc | Compounds and compositions and uses thereof |
| AU2017301769B2 (en) | 2016-07-29 | 2022-07-28 | Pgi Drug Discovery Llc | Compounds and compositions and uses thereof |
| AU2018220509B2 (en) | 2017-02-16 | 2022-04-28 | Sumitomo Pharma America, Inc. | Methods of treating schizophrenia |
| CN109280030B (zh) * | 2017-07-19 | 2022-04-22 | 江苏恩华药业股份有限公司 | 苯骈氮杂烷基芳基哌嗪衍生物及在制备药物中的应用 |
| SG11202000669VA (en) | 2017-08-02 | 2020-02-27 | Sunovion Pharmaceuticals Inc | Isochroman compounds and uses thereof |
| CA3091292A1 (en) | 2018-02-16 | 2019-08-22 | Sunovion Pharmaceuticals Inc. | Salts, crystal forms, and production methods thereof |
| JP7703449B2 (ja) | 2019-03-14 | 2025-07-07 | スミトモ・ファーマ・アメリカ・インコーポレイテッド | イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物 |
| CN115734785A (zh) | 2020-04-14 | 2023-03-03 | 桑诺维恩药品公司 | (S)-(4,5-二氢-7H-噻吩并[2,3-c]吡喃-7-基)-N-甲基甲胺用于治疗神经和精神方面的病症 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3509153A (en) * | 1967-03-24 | 1970-04-28 | Miles Lab | 5-phenyl (or 5-phenylalkyl)-2-(omega-(4-phenyl-1-piperazinyl)alkyl)tetrazoles |
| US3647790A (en) * | 1969-04-08 | 1972-03-07 | American Home Prod | Ouinoxalinyl-oxazolidines and -oxazines |
| ES378315A1 (es) * | 1969-04-11 | 1972-06-01 | Robins Co Inc A H | Un procedimiento para la preparacion de 1 - (omega-susti- tuido-alcohil)-2-metilbenzimidazoles. |
| JPS5011395B1 (de) * | 1970-12-29 | 1975-04-30 | ||
| NZ181256A (en) * | 1975-07-21 | 1978-04-28 | Janssen Pharmaceutica Nv | 1-(w-benzazol-11-ylalkyl)-piperidine derivatives and pharmaceutical compositions containing certain of these derivatives |
| US3981881A (en) * | 1975-08-14 | 1976-09-21 | E. R. Squibb & Sons, Inc. | 2-[(4-Phenyl-tetrahydropyridinyl)alkyl]-1H-isoindole-1,3(2H)-diones |
| US3994904A (en) * | 1976-03-08 | 1976-11-30 | Miles Laboratories, Inc. | 3-Substituted -5-phenyl-5-pyridyl hydantoins |
| JPS5746983A (en) * | 1980-09-04 | 1982-03-17 | Eisai Co Ltd | Theophylline derivative and its preparation |
| EP0087810B1 (de) * | 1982-03-02 | 1986-06-25 | Eisai Co., Ltd. | Antiphlogistische antipyretische analgesische pharmazeutische Zusammensetzungen mit Theophyllin-Derivaten als wirksame Bestandteile |
| JPS58150511A (ja) * | 1982-03-02 | 1983-09-07 | Eisai Co Ltd | テオフイリン誘導体を有効成分とする脳循環代謝改善剤 |
| US4539407A (en) * | 1983-12-13 | 1985-09-03 | American Home Products Corporation | β-Carboline anticonvulsants |
| US4675403A (en) * | 1985-10-16 | 1987-06-23 | American Home Products Corporation | 3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity |
| US4754038A (en) * | 1987-02-26 | 1988-06-28 | American Home Products Corporation | Carboline histamine H1 antagonists |
| US5296487A (en) * | 1990-01-02 | 1994-03-22 | Fujisawa Pharmaceutical Co., Ltd. | Quinazoline derivatives and their preparation |
| DE69021855T2 (de) * | 1990-01-02 | 1996-02-29 | Fujisawa Pharmaceutical Co | Quinazolinderivate und ihre Herstellung. |
| FR2672052B1 (fr) * | 1991-01-28 | 1995-05-24 | Esteve Labor Dr | Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments. |
| JP3198117B2 (ja) * | 1990-02-07 | 2001-08-13 | サントリー株式会社 | ピロロアゼピン誘導体 |
| US5149817A (en) * | 1990-03-05 | 1992-09-22 | Shionogi & Co., Ltd. | Teirahydropyridine derivatives |
| JPH04211059A (ja) * | 1990-03-05 | 1992-08-03 | Shionogi & Co Ltd | 新規なテトラヒドロピリジン誘導体 |
| FR2671972B1 (fr) * | 1991-01-25 | 1995-03-03 | Esteve Labor Dr | Utilisation de derives 1-h-azole-(omega-(4-(2-pyrimidinyl)-1-piperazinyl)-alkyl) pour la preparation de medicaments destines au traitement des troubles des fonctions cognitives. |
| FR2673628B1 (fr) * | 1991-03-07 | 1993-07-09 | Esteve Labor Dr | Procede de preparation de derives d'aryl (ou heteroaryl)-piperazinyl-butyl-azoles. |
| JP3219281B2 (ja) * | 1991-04-03 | 2001-10-15 | 聰 竹尾 | 心筋保護剤 |
| DK148392D0 (da) * | 1992-12-09 | 1992-12-09 | Lundbeck & Co As H | Heterocykliske forbindelser |
| WO1995003298A1 (en) * | 1993-07-19 | 1995-02-02 | Fujisawa Pharmaceutical Co., Ltd. | BENZIMIDAZOLE DERIVATIVES USEFUL AS DOPAMINE RECEPTOR ANTAGONIST, 5-HT RECEPTOR AGONIST OR α1 RECEPTOR ANTAGONIST |
| US5411960A (en) * | 1993-12-09 | 1995-05-02 | Bayer Aktiengesellschaft | Substituted pyrroloanthracenes and -diones |
| FR2723091B1 (fr) * | 1994-07-29 | 1996-11-08 | Esteve Labor Dr | Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles |
-
1994
- 1994-07-29 FR FR9409443A patent/FR2723091B1/fr not_active Expired - Fee Related
-
1995
- 1995-06-07 US US08/473,066 patent/US5731331A/en not_active Expired - Lifetime
- 1995-07-26 DK DK95928478T patent/DK0721455T3/da active
- 1995-07-26 PL PL95313716A patent/PL183766B1/pl not_active IP Right Cessation
- 1995-07-26 HU HU9600815A patent/HU220088B/hu not_active IP Right Cessation
- 1995-07-26 WO PCT/EP1995/002978 patent/WO1996004287A1/fr not_active Ceased
- 1995-07-26 BR BR9506292A patent/BR9506292A/pt not_active IP Right Cessation
- 1995-07-26 CN CN95190813A patent/CN1120167C/zh not_active Expired - Fee Related
- 1995-07-26 RU RU96110883/04A patent/RU2168507C2/ru not_active IP Right Cessation
- 1995-07-26 PT PT95928478T patent/PT721455E/pt unknown
- 1995-07-26 NZ NZ291172A patent/NZ291172A/en unknown
- 1995-07-26 KR KR1019960701606A patent/KR100389785B1/ko not_active Expired - Fee Related
- 1995-07-26 DE DE69529142T patent/DE69529142T2/de not_active Expired - Lifetime
- 1995-07-26 EP EP95928478A patent/EP0721455B9/de not_active Expired - Lifetime
- 1995-07-26 JP JP50617496A patent/JP4035787B2/ja not_active Expired - Fee Related
- 1995-07-26 CA CA002172986A patent/CA2172986A1/fr not_active Abandoned
- 1995-07-26 AU AU32225/95A patent/AU712479B2/en not_active Ceased
- 1995-07-26 CZ CZ1996926A patent/CZ293123B6/cs not_active IP Right Cessation
- 1995-07-26 AT AT95928478T patent/ATE229530T1/de not_active IP Right Cessation
- 1995-07-28 ZA ZA956314A patent/ZA956314B/xx unknown
-
1996
- 1996-03-25 NO NO961207A patent/NO309379B1/no unknown
- 1996-03-28 FI FI961412A patent/FI116386B/fi not_active IP Right Cessation
-
1998
- 1998-02-26 US US09/031,024 patent/US6232329B1/en not_active Expired - Fee Related
-
2006
- 2006-09-27 JP JP2006290515A patent/JP2007051154A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE229530T1 (de) | Tetrahydropyridin-(oder 4-hydroxypiperidin) alkylazole mit sigma und/oder 5ht 1a-rezeptor aktivität | |
| DE69715862D1 (de) | Verwendung eines k-252a derivats zur behandlung von periphärer oder zentraler nervenerkrankungen und übermässiger cytokinbildung | |
| ATE412415T1 (de) | Inhibitoren der phosphodiesterase der zyklischen nucleotiden, mit einer benzodiazepinischen struktur, und deren verwendung in therapie | |
| NO971816D0 (no) | Farmasöytisk blanding for behandling av sykdommer forårsaket av IL-6 produksjon | |
| IE900456L (en) | Improvements in and relating to organic compounds | |
| MXPA05003734A (es) | Inhibidores de acetilcolinesterasa en el sitio de enlace dual para el tratamiento de la enfermedad de alzheimer. | |
| GR3019782T3 (en) | Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents | |
| EP1043983A4 (de) | Tetracycline und/oder tetracyclinderivate zur behandlung und prophylaxe von cerebrovascularen krankheiten des nervensystems | |
| DE69618047D1 (de) | Verwendung von Serotonin- und Dopaminrezeptorblockern zur Behandlung von mentalen Erkrankungen verursacht durch zerebrovaskuläre Erkrankungen | |
| BR9406034A (pt) | Derivados de imidazoloquinoxalinonas como antagonistas de eaa. | |
| ATE334680T1 (de) | 4-aminopiperidin-derivate, verfahren zur herstellung und ihre verwendung als arzneimittel | |
| NO883605D0 (no) | Optiske isomerer av et spiroquinuklidinderivat. | |
| ES2117934A1 (es) | Tetrahidropiridinas (0 4-hidroxipiperidinas) alquilazoles. | |
| TW367320B (en) | Novel aryl compounds having CNS activity, process for their preparation and their use as medicaments | |
| NO993126D0 (no) | Anvendelse av benzoylalkyl-1,2,3,6-tetrahydropyridiner | |
| ATE205499T1 (de) | Heterocyclische verbindungen, deren herstellung und verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0721455 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |